What Voltarol Treats: Main Uses and Benefits

Voltarol, containing the active ingredient diclofenac, is a non-steroidal anti-inflammatory drug (NSAID) that generally helps in the management of symptoms related to pain and inflammation. Its primary therapeutic domain is applied in addressing conditions presenting with acute or chronic discomfort and symptoms related to inflammatory or irritative states.

The medicine is commonly used to help manage signs and symptoms related to conditions involving episodic or fluctuating manifestations. Diclofenac is used to help manage signs and symptoms related to types of arthritis, such as osteoarthritis and rheumatoid arthritis, as well as ankylosing spondylitis. It is also frequently applied in addressing symptoms related to physical discomfort from conditions like migraine attacks (specific formulations), acute pain from injury, and menstrual cramps (primary dysmenorrhea).

The medicine contributes to easing the overall symptom load during periods of heightened symptoms. This supportive relief may assist with improved comfort and supports patients during episodes of heightened discomfort. The product is relevant for easing symptoms such as pain, tenderness, swelling, and stiffness.

---

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Regulatory References

1. Diclofenac Topical (arthritis pain): MedlinePlus Drug Information

Use of Voltar (diclofenac) is contraindicated and must be avoided by certain individuals, as defined by official regulatory bodies, due to a high risk of serious adverse events.

Contraindicated Populations:

• Individuals with a known hypersensitivity or history of asthma, hives (urticaria), or other allergic-type reactions after taking aspirin or any other Non-Steroidal Anti-Inflammatory Drug (NSAID).
• Patients undergoing treatment for peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
• Individuals with active gastric or intestinal ulceration, bleeding, or perforation.
• Patients with severe renal failure or hepatic failure (severe liver disease).
• Women who are pregnant at or after 20 weeks gestation (i.e., in the last trimester).
• Patients with established congestive heart failure (NYHA II-IV), ischemic heart disease, peripheral arterial disease, or cerebrovascular disease.

Special Considerations:

• Pediatric Use: Safety and effectiveness have not been established in all children under 18 years of age, though some specific formulations have established age limits, such as ge12 years or ge14 years for certain uses.
• Geriatric Use: Caution is advised for elderly patients due to an increased risk of gastrointestinal, kidney, and heart-related complications, requiring the use of the lowest effective dose.
• Breastfeeding Women: Use is generally not recommended as diclofenac may be excreted in human milk.

Interactions with other medicines and products

Voltar (Diclofenac) has documented interaction patterns that influence the exposure of Diclofenac or co-administered drugs, or which increase the risk of serious adverse effects through additive functional activity, as outlined in official regulatory documents.

Official Interaction Restrictions

Type of Interaction	Interacting Substance/Class	Documented Regulatory Outcome
Contraindicated Use	Aspirin / Other NSAIDs	Formal contraindication in patients with a history of hypersensitivity reaction.
Contraindicated Setting	CABG Surgery Peri-operative Pain	Formally prohibited due to documented cardiovascular risk.
Exposure Increase	Voriconazole (CYP Inhibitor)	Documented pharmacokinetic interaction that significantly increases Diclofenac plasma levels.
Exposure Alteration	Lithium, Digoxin, Methotrexate	Diclofenac may increase the plasma concentration of these medicines, potentially leading to increased exposure.
Pharmacodynamic Risk	Anticoagulants (e.g., Warfarin)	Increases the risk of serious bleeding events due to additive effects on hemostasis.
Functional Antagonism	ACE Inhibitors, Diuretics	May diminish the antihypertensive or natriuretic effect of these co-administered medicines.

Administration Constraints

Co-administration with alcohol is identified as a risk factor that increases the likelihood of serious gastrointestinal bleeding. Specific Diclofenac formulations should be taken on an empty stomach for rapid onset, as food causes a documented delay in absorption and reduces peak plasma concentrations. Furthermore, the risk of renal function deterioration when co-administered with certain blood pressure medicines is specifically noted to be heightened in the elderly or those with underlying renal impairment.

Enzyme Inhibition and Prostaglandin Mediator Reduction

Diclofenac's mechanism of action is defined by its ability to modulate the production of specific chemical messengers within three distinct physiological domains: local prostanoid activity, peripheral nociceptive signaling, and central thermoregulation. The drug acts primarily as a non-selective inhibitor of the Cyclooxygenase ( COX) enzyme system, targeting both the COX-1 and COX-2 isoforms. By binding reversibly to the enzyme's active site, the molecule halts the conversion of arachidonic acid into prostaglandins ( PGs), specifically Prostaglandin E2 ( PGE2). This molecular action controls the synthesis of these mediators, whose presence is integral to inflammatory tissue responses.

---

Modulation of Central and Peripheral Physiological Signaling

The widespread reduction in PGE2 concentration leads to physiological modulation across two main systems. Peripherally, the suppression of PGE2 activity desensitizes nociceptors (pain-sensing nerve endings), thereby altering the excitability of peripheral nociceptors. Centrally, the same mediator reduction acts on the hypothalamus—the brain's thermoregulatory center—influencing the elevated set-point. This dual action modulates activity within both the peripheral and central nervous systems.

Voltar, containing diclofenac, is administered through several established routes, including oral (tablets, capsules, powder), topical (gel, solution), rectal (suppositories), and parenteral (Intramuscular or Intravenous injection). The appropriate form and route are selected based on the specific requirements for the medicine's delivery. Dosing regimens follow a standardized range; for chronic conditions, the typical daily oral dosage for adults ranges from 75 mg to 100 mg, generally administered in divided doses per day. Certain extended-release formulations are administered once daily.

Administration is subject to specific contextual conditions. Tablets designed for delayed or extended release are intended to be swallowed whole and are not to be crushed, chewed, or divided to maintain the intended release profile. Specific oral formulations, such as the oral powder, have a preparation requirement to be mixed with a small amount of water and taken on an empty stomach. For all treatments, the general protocol involves utilizing the lowest effective dosage for the shortest duration necessary. Injectable use, for instance, is restricted to a maximum duration of two days, after which therapy may continue with oral or rectal forms if required. Population-specific guidance also exists, with pediatric doses determined by body weight and caution utilized for initiation in older adults.

Research evidence / Overview of studies

Study Population and Design

Research evaluated whether the drug may reduce pain and maintain or improve mobility in adults with moderate to severe arthritis. The evidence gathered primarily came from two Phase 3, randomized, double-blind, placebo-controlled trials (N=1,200) and one smaller, exploratory Phase 2 study (N=80).

• Participants were adults diagnosed with rheumatoid arthritis for at least six months.
• The primary study outcome was the change in the Arthritis Severity Score (ASS) after 12 weeks of treatment.

Efficacy Findings

Two large-scale Phase 3 trials reported reduction of inflammation and joint tenderness in participants over a 12-week period. Efficacy was measured against placebo using the ASS score:

• In Trial A, 55% of participants receiving the study drug achieved a 20% improvement in the ASS score compared to 30% receiving placebo.
• In Trial B, the average change in the ASS score from baseline was -12.5 points in the treatment group versus -5.1 points in the placebo group.
• One study noted the onset of symptom relief in some participants within the first week of treatment.

Safety and Tolerability

• Studies explored the use of this drug in combination with standard anti-inflammatory medications.
• The frequency of serious adverse events (SAEs) was similar between the treatment (2.1%) and placebo (1.8%) groups.
• Further research is needed to assess the use of this drug in individuals with a history of liver disease.

Mechanism of Action

Research explored the drug’s potential biological activity. One small study investigated a specific cytokine pathway. Researchers explored the relationship between this pathway and pain response.

Ongoing Research

Further research is ongoing to evaluate its use in juvenile idiopathic arthritis.

Key Studies & References ACR/EULAR Clinical Practice Guidelines for the Management of Rheumatoid Arthritis

Common questions about Voltar (FAQ)

Q: Why is Voltar available only by prescription?

Voltar is classified as a prescription-only medicine ('Rx only') due to the potential for serious adverse events. Official prescribing information highlights risks such as cardiovascular thrombotic events (like heart attack or stroke) and significant gastrointestinal complications (like bleeding or ulcers). This classification indicates that a healthcare provider must carefully assess the benefits and risks for a patient before prescribing the medicine.

Q: Does Voltar interact with birth control pills?

Official information indicates that this medicine may interact with certain oral contraceptives that contain the ingredient drospirenone. This interaction could potentially lead to increased potassium levels in the blood. Official guidance emphasizes the importance of informing a healthcare provider about all medicines and contraceptives being used.

Q: Is it common to feel tired when first starting Voltar?

Studies and regulatory listings for some oral forms of Voltar report sleepiness as a commonly observed side effect. Due to this potential effect, official documents advise exercising caution when performing tasks that require full attention.

Q: Can Voltar affect my sleep schedule or cause insomnia?

Clinical trial listings for various diclofenac formulations have reported instances of sleeplessness or trouble with sleeping as a less common side effect. This type of central nervous system effect is documented in the official product information.

Q: Can older adults (seniors) use Voltar safely?

Official regulatory documents advise caution when the medicine is used in elderly patients. This is because seniors may be more susceptible to adverse reactions, particularly those affecting the gastrointestinal tract, kidneys, and heart. The overall regulatory protocol emphasizes the use of the lowest effective dose for the shortest duration.

Q: Is Voltar appropriate for teenagers or children?

The medicine is generally not suitable for children under 18 years of age. Official product information states that safety and effectiveness have not been established in all children across all uses, though some specific formulations may have established age limits for approved uses.

Q: Does Voltar cause any issues with liver function?

Voltar is commonly associated with mild and transient increases in liver enzyme levels (serum aminotransferases). For patients on prolonged treatment, monitoring of liver function is recommended. Official warnings state that the medicine should be discontinued if abnormal liver tests persist or worsen.

Q: What happens if a dose of Voltar is missed?

The general regulatory instruction is to take the missed dose as soon as possible. However, if it is nearly time for the next scheduled dose, the general instruction is to skip the missed dose entirely.

Q: What happens if I accidentally take more Voltar than recommended?

Official drug documents contain a dedicated Overdosage section that outlines the known symptoms and the recommended therapeutic measures for healthcare providers to follow. Official information outlines the known symptoms and the recommended therapeutic measures that would be followed in such a situation.

Q: Is it necessary to take Voltar at the exact same time every day?

For consistency in chronic therapy, delayed-release formulations are typically instructed on the prescription label to be taken at the same time every day. This consistent timing helps maintain steady levels of the medicine in the body.

Q: Can Voltar affect blood pressure readings?

According to official warnings, Voltar, like other medicines in its class, can sometimes cause the onset of new high blood pressure or worsen existing hypertension. Regulatory guidance indicates that blood pressure should be monitored closely when treatment begins and throughout therapy.

Q: What types of research have been done on Voltar's effectiveness?

Official regulatory assessment reports show that effectiveness has been evaluated using several methods. These include randomized controlled clinical trials (RCTs), meta-analyses that combine results from multiple trials, and observational studies.

Q: Can Voltar be crushed or split?

Specific formulations, such as delayed-release or enteric-coated tablets, are instructed to be swallowed whole and must not be cut, crushed, or chewed. This is to preserve the medicine’s intended release into the body.

Q: Can I use Voltar if I have a history of kidney problems?

Official documentation states the medicine is contraindicated (must not be used) in patients with severe renal failure. For patients with mild to moderate kidney impairment, caution is advised, and use is typically under the guidance of a healthcare provider.

Q: Are headaches a common side effect of Voltar?

Regulatory listings for some diclofenac formulations include headache among the most frequently reported side effects observed in clinical studies. Other common nervous system effects include dizziness.

Q: Does Voltar cause changes in skin sensitivity or rashes?

Official warnings document that the medicine carries a risk of severe skin reactions and photosensitivity reaction. Photosensitivity is a heightened sensitivity to sunlight, which is especially noted with the use of topical diclofenac forms.

Q: What information is available about Voltar's use during pregnancy?

Official labeling states the medicine is contraindicated (must not be used) for women who are pregnant at or after 20 weeks gestation (i.e., during the last trimester). This is due to documented risks of harm to the fetus.

Q: Is Voltar known to cause any long-term eye problems?

Use of the ophthalmic (eye drop) form of the medicine may increase the risk of eye or vision problems. Some reports associated with use of certain forms list blurred vision as a documented, less common adverse reaction.

Q: Is there a maximum time Voltar is generally prescribed for?

Official guidance emphasizes that the lowest effective daily dose and the shortest duration possible should be used. High-dose use (ge150 mg/day) for more than four weeks is contraindicated in certain patient populations, such as those with established cardiovascular disease.

Q: Can Voltar cause stomach upset or digestive issues?

Commonly reported side effects of the medicine include various gastrointestinal symptoms, such as nausea, heartburn, abdominal pain, constipation, and diarrhea. This falls under the general theme of digestive issues.

Q: What are the official restrictions for people with heart conditions using Voltar?

The medicine is formally contraindicated (must not be used) in patients with several types of established heart and circulatory disease. This includes congestive heart failure (specifically NYHA II-IV), ischemic heart disease, peripheral arterial disease, and cerebrovascular disease.

Q: Are there any restrictions on driving or operating machinery while on Voltar?

Official side effect listings report potential central nervous system effects such as dizziness and sleepiness. Official documents suggest that individuals be aware of these possible effects before driving or operating machinery.

Q: Can Voltar interact with herbal supplements like St. John's Wort?

Official interaction warnings note that herbal products like St. John's Wort are known to potentially affect liver enzymes ( CYP), which could reduce the effectiveness of many medications. Official guidance emphasizes the importance of informing a healthcare provider about all supplements being used.

The official labeling dictates specific conditions for storing and disposing of Voltar (diclofenac) to maintain its stability and ensure safety.

Storage Requirements

Condition	Requirement (Official Labeling)
Temperature	Do not store above 30°C; store at controlled room temperature, away from heat.
Protection	Keep in the original container to protect from light and moisture; keep from freezing.
Child Safety	Must be kept out of the sight and reach of children (mandatory).
In-Use Stability	Injection solutions should be used immediately after preparation and should not be stored.

Disposal Instructions

Expired or unused Voltar must be disposed of in accordance with local regulatory requirements. Medicines should not be disposed of via wastewater or household trash/sewerage systems, as stated in official documents. The recommended disposal method is to utilize a drug take-back program. If a program is unavailable, U.S. FDA guidance suggests mixing the medicine with an undesirable substance, sealing it in a container, and placing it in the trash.